Search Results for “healthcare” – media

Celltrion expands European market, acquires iQone Healthcare for 30 billion

On Friday, South Korean biosimilar giant Celltrion said it had completed the acquisition of iQone Healthcare Switzerland for approximately 30 billion won (about 155 million yuan) as part of its European expansion strategy. After the acquisition, iQone Healthcare Switzerland will become a wholly-owned subsidiary of Celltrion Healthcare Hungary Kft. The transaction will also provide Celltrion with the opportunity to obtain authorizations, further enhancing its pipeline of innovative therapies. In 2022, iQone’s annual revenue was 18.9 billion won (about 18.9 million US dollars), and sales increased by 57% to 29.6 billion won in 2023. Celltrion said the acquisition will further accelerate the expansion of its prescription drug business in Switzerland. According to IQVIA data, sales performance in the country remains strong, with the Ramsima series (IV and SC) accounting for 61% of the market share in the second quarter of this year. The company noted that its follow-up products are expected ...
- Source: drugdu
- 41
- November 20, 2024
Consumer healthcare leaders collectively stagnate

The third quarter of 2024 is an epoch-making watershed. An unprecedented large-scale stagnation has occurred in the consumer healthcare field. From medical beauty, ophthalmology, dentistry, pharmaceutical retail, branded Chinese medicine, growth hormone to self-funded vaccines, the leaders in various segments have become old and collectively lost their growth potential. The mismatch between business model, product structure and consumer market is one of the reasons for the predicament, but it is so difficult for a company to get out of the path dependence that created its former glory. Now there are two problems. First, how does the market value companies that have lost their growth but are still profitable? When a company stops growing, the only investment attraction is high dividends, but consumer healthcare companies are almost all stingy. Second, when will consumption pick up? When will the consumption inflection point come? Japan’s situation from 1990 to 1997 is inspiring. Consumption ...
- Source: drugdu
- 55
- November 13, 2024
The “trend” and “newness” behind Roche Pharmaceuticals’ layout of smart healthcare in China

Never underestimate the power of the tide. “AI+ empowerment” is becoming an important engine to promote the expansion of new quality productivity in various industries, and the medical and health system is no exception. For the medical and health system, improving productivity and efficiency while reducing the cost of patients and healthcare systems is an eternal topic. This also means that the greatest potential of AI+ healthcare lies not only in the application of one or two scenarios, but in assisting and optimizing medical services in all aspects, and completely rewriting the order of all links of “diagnosis and treatment”. At this year’s CIIE, through the display of Roche, the industry leader, we can see that this trend is already very obvious: AI is penetrating in multiple dimensions to meet the individualized diagnosis and treatment needs of patients and change the direction of the tide in multiple fields. Although many ...
- Source: drugdu
- 59
- November 12, 2024
GE Healthcare, this product is being produced for the first time in the United States

Recently, GE Healthcare is manufacturing the integrated Omni Legend PET/CT at its new production facility in Wisconsin. This marks the first time that the system has been produced domestically in the United States. 01. Innovative product Omni Legend PET/CT GE HealthCare launched its first PET/CT: Omni Legend on the fully digital Omni platform at the European Association for Nuclear Medicine (EANM) annual meeting in October 2022. The system achieved significant improvements in sensitivity, efficiency, radiation dose, and patient comfort. The system is equipped with a new digital BGO (dBGO) detector, aimed at improving examination efficiency, enhancing patient experience, and boosting diagnostic confidence. The system adopts a new category of digital BGO (dBGO) detector materials, with small crystal size and sensitivity more than twice that of existing digital scanners, which can achieve faster total scanning time and impressive small lesion detectability It aims to improve operational efficiency, enhance patient experience, and ...
- Source: drugdu
- 66
- October 30, 2024
Eight commonly used immune cell therapies open up a new era of healthcare

Introduction: The era of chemotherapy cannot solve the “pain points” of relapsed and refractory diffuse large B-cell lymphoma, but the era of new cell drugs has solved them. And this new cellular drug, CAR-T cell therapy, which has become a hot topic in recent years, has opened up a new era of medical treatment, with a market size of trillions of dollars. Immune cell therapy aims to enhance the immune system’s ability to fight cancer. Manufacturing cell therapy requires collecting a specific set of cells from the blood, modifying them to produce more powerful attacks on the patient’s cancer cells, and then re injecting them into the patient’s body. At present, many types of cancer cell therapies are being explored, including CAR-T cells, other genetically modified T cells, tumor infiltrating lymphocytes (TIL), NK cells, CIK cells, B cells, etc. Extracting immune cells from patients’ bodies and modifying them to make ...
- Source: drugdu
- 76
- October 26, 2024
GE Healthcare launches its first CT production line in the country

Recently, GE Healthcare launched its first CT production line in France, marking a significant expansion of the company’s business at its Booker factory in the Yvelines department of France. It is reported that the new production line was announced in 2023 with the aim of improving the company’s agility, reducing carbon emissions, and better serving European customers. At present, the first scanner assembled in France, the Revolution Maxima CT, has been installed in the emergency department of Montargis Hospital Center in Loiret. The assembly of Revolution Maxima CT at Buc factory includes all functions and X-ray testing, system configuration, and direct delivery to European customers, which helps simplify the supply chain. It is understood that the new production line is part of GE Healthcare’s “In Europe for Europe” program, which is expected to reduce carbon emissions related to scanner transportation in Europe by 84%. This reduction is mainly due to ...
- Source: drugdu
- 78
- October 24, 2024
What does it mean to have a dual system in healthcare?

On September 8, the Ministry of Commerce, the National Health Commission, and the State Food and Drug Administration jointly issued the Notice on Carrying out Pilot Work on Expanding Opening-up in the Medical Field (hereinafter referred to as the “Notice”). It is proposed to allow the establishment of wholly foreign-owned hospitals (except for traditional Chinese medicine, excluding mergers and acquisitions of public hospitals) in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and Hainan. This is undoubtedly a bold innovation to the existing healthcare system. Previously, foreign investment was limited to joint venture hospitals, and there were many restrictions such as shareholding ratio. With the relaxation of policy restrictions and the introduction of foreign-funded medical institutions, as more high-end medical institutions enter the Chinese market, while diverting some high-end patients, it may also improve the development and progress of the overall medical level in China. There are two main points ...
- Source: drugdu
- 91
- October 6, 2024
In 2024, consumer healthcare will have a hard time

According to statistics from Guangdong Securities, the domestic consumer healthcare market size corresponds to a trillion-level market. Among them, the market size of specialized medical fields such as ophthalmology, stomatology, and assisted reproduction can reach 382.62 billion yuan, and is expected to reach 605.88 billion yuan in 2025; the market size of the medical beauty field has reached 226.7 billion yuan, and is expected to reach 352.9 billion yuan in 2025. In such a vast market, growth should be the first priority. However, after the epidemic, the expected consumption recovery and rebound have not arrived. Since the third quarter of last year, the overall economic environment has continued to weaken, and the operating pressure of sub-industries such as medical services, consumer equipment, and medical beauty with consumer attributes has increased, and most of them have not met expectations. This was particularly evident in the second quarter of this year, and ...
- Source: drugdu
- 90
- September 7, 2024
Growth of United Imaging Healthcare has Slowed Down, Leading to a Continuous Decline in its Stock Price

Recently, Shanghai United Imaging Healthcare Co., Ltd. (also known as, United Imaging Healthcare) released its 2024 semi annual report, with a revenue of 5.333 billion yuan in the first half of the year, a year-on-year increase of 1.18%; Realize a net profit attributable to the parent company of 950 million yuan, a year-on-year increase of 1.33%; Deducting non attributable net profit of 798 million yuan, a year-on-year increase of 1.39%. The growth of Zhonglian Film Medical has slowed down in the semi annual report, leading to a continuous decline in its stock price. Now that the market value of United Imaging Healthcare is not guaranteed at billions, how can the new rich break through the situation? CT business is sluggish, with a market value of billions falling Founded in 2011, United Imaging Healthcare is committed to providing global customers with a full range of independently developed high-performance medical imaging diagnosis ...
- Source: drugdu
- 90
- September 5, 2024
Internet healthcare is more than just selling drugs

Can the business model of Internet healthcare work without selling drugs? This may be the answer that everyone wants to know at the moment. After all, Internet healthcare is recognized as a tough nut to crack. Many entrants have fallen halfway, and some survivors are not in a good situation. Ping An Health’s latest semi-annual report finally gave a definite answer. In the first half of the year, Ping An Health’s adjusted net profit reached 89.74 million yuan, a year-on-year loss of 340 million yuan. This achievement was not easy to come by. Ten years after its establishment, Ping An Health finally achieved its first profit; if compared with JD Health and Ali Health, Ping An Health’s turnaround time is also later, but the latter’s turnaround may be more meaningful to the entire Internet healthcare. The core is that, in the eyes of the outside world, whether it is JD ...
- Source: drugdu
- 75
- August 31, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.